Markus Altwegg (1941) joined the Board of Siegfried Holding AG in 2002 and - following his withdrawal from the Roche Executive Committee – was appointed Chairman in 2003. He will not be available for re-election at the next annual meeting of shareholders due to age. In addition, Susy Brüschweiler (1947), Chairwoman of SV-Stiftung, and Prof. Felix Gutzwiller (1948) will not stand for re-election. Both joined the Board in 1999.
The following candidates stand to join the Board of Siegfried Holding AG:
- Gilbert Achermann (1964) is designated as Chairman of Siegfried Holding AG in addition to his activities at Straumann.
- Reto A. Garzetti (1960) is Partner in SE Swiss Equities, a Zurich-based asset management company.
- Beat In-Albon (1952) is Head of SGS Group’s Industrial Services Division.
- Thomas Villiger (1951) is a business consultant and former CEO of Mepha.
The annual general meeting of Siegfried Holding AG is to be held in Zofingen on May 24, 2011.
Biographical sketches
Dr. Markus Altwegg
Markus Altwegg (1941) joined the Board of Siegfried Holding AG in 2002 and was appointed its Chairman in 2003. From 1999 to 2003 he was responsible for the international business of Roche Group’s Vitamins and Fine Chemicals Division. Preceding that to that he held various other functions in other departments at Roche, in Switzerland and abroad. He was appointed to Roche’s Executive Committee in 1986.
He furthermore serves on the Board of Energiedienst Holding AG and private bank Sal. Oppenheim AG. He is also a member of numerous industry associations and scientific and charity associations. He is Chairman of the Foundation for the Kunstmuseum Basel, a committee member of the Foundation for the Basel Museum of Ancient Art, a member of the Board of Unitectra, the Technology Transfer Organization of the Universities of Basel, Bern and Zurich. He holds a Ph.D. in Economics from the University of Basel.
Susy Brüschweiler
Susy Brüschweiler (1947) joined the Board of Siegfried Holding AG in 1999. Following training as a hospital nurse she continued her studies in economics and business administration at the University of Neuchâtel. In 1986 she was appointed head of the Bois- Cerf Nursing School in Lausanne and in 1990 Director of the Specialist Training College for Nursing in Aarau. In 1995 she was appointed head of the former Verein SV-Service, today SV-Group, a position she held until 2010. Subsequently she was appointed Chairwoman of the SV Foundation.
Susy Brüschweiler is also on the Boards of Schweizerische Mobiliar Holding AG, Schweizerische Mobiliar Genossenschaft AG. She serves on the Board of the Swiss Paraplegics Association. Susy Brüschweiler is a Honorary Member of the International Committee of the Red Cross (ICRC).
Felix Gutzwiller, Councellor of State
Felix Gutzwiller (1948) joined the Board of Siegfried Holding AG in 1999. He was appointed professor of preventive medicine at the University of Zurich in 1988 and Head of that university institute. He served the Swiss Parliament as a Member from 1999 to 2007 and as a Councilor of State since 2007. Felix Gutzwiller graduated from the Universities of Basel, Harvard and Johns Hopkins (USA).
In addition to his mandate for Siegfried Holding AG, Felix Gutzwiller serves on the Boards of Bank Clariden Leu AG and Axa Winterthur Switzerland AG as well as on several boards of trustees in the areas of charity, science and public health. Felix Gutzwiller is a colonel in the Swiss Army.
Gilbert Achermann
Gilbert Achermann (1964) joined the Board of Straumann in 2009 and was appointed Chairman in April 2010. He joined Straumann in 1998 as CFO and was appointed CEO in 2002. He held this function until the annual general meeting of Straumann at the end of May 2010. Preceding his employment by Straumann, Achermann worked for UBS in Zurich, Geneva, New York and Frankfurt in the fields of Corporate Finance and Sales & Trading.
Gilbert Achermann also serves on the Board of the International Team for Implantology (ITI), and he is a member of the advisory committee for international cooperation of Canton Basel-Stadt.
Gilbert Achermann holds an Executive MBA degree from IMD Lausanne and a degree in business administration from the University for Applied Sciencies of St. Gallen.
Reto A. Garzetti
Reto A. Garzetti (1960) is a partner of SE Swiss Equities, a Zurich-based asset management company (former Schweizerische Gesellschaft für Aktienhandel und Research AG). Preceding that he worked during 10 years for Berater Zentrum AG. Until 2010 he served on the Board of this company.
He graduated from the University of Zurich in business administration (lic. oec. publ.) with the main emphasis on banking and law for trade and securities.
Beat In-Albon
Beat In-Albon (1952) is a member of the Executive Board of Geneva-based SGS Group and Head of its Industrial Services Division. Preceding that he was employed for 20 years by the Lonza Group where he was Head of the Organic Fine & Performance Chemicals Division and member of the Executive Board.
He holds a Ph.D. degree in economics from the University of Fribourg (1983).
Thomas Villiger
Thomas Villiger (1951) founded his own management consultancy in 2010. From 1986 to 2010 he was employed by Mepha Group, from 1997 onward he leaded the Mepha Group as a CEO. From 1980 – 1986 he worked in various functions for Sandoz in Basel, partly in Japan. He serves on the boards of Dolder AG and the Sigvaris Holding AG.
He holds a Ph.D. degree in chemistry from the Swiss Federal Institute of Technology in Zurich (1979).
For further information:
Peter Gehler, Chief Communication Officer Phone +41 (0)62 746 11 44, Fax +41 (0)62 746 11 03, Mobile +41 (0)79 416 41 16 peter.gehler@siegfried.ch
Siegfried Holding AG Untere Brühlstrasse 4 CH-4800 Zofingen Tel. +41 (0)62 746 11 11 Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried
Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products with production facilities located in Switzerland, Malta and the USA. At the end of 2009, Siegfried employed approximately 850 employees and achieved annual sales of roughly CHF 283 million.
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and standard products, and provides development and production services for drugs in finished dosage forms.
Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SIX: SFZN).
